SEC	Form	4

FORM 4

Check this box if no longer subject to

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
_	

1. Name and Address of Reporting Person* Gerber Hans-Peter		*	2. Issuer Name and Ticker or Trading Symbol <u>SUTRO BIOPHARMA, INC.</u> [STRO]		tionship of Reporting Pers all applicable) Director	on(s) to Issuer 10% Owner			
(Last) C/O SUTRO BIO	(Last) (First) (Middle) C/O SUTRO BIOPHARMA, INC.		 3. Date of Earliest Transaction (Month/Day/Year) 04/04/2025 	x	Officer (give title below) CHIEF SCIENTIF	Other (specify below)			
111 OYSTER POINT BLVD.			4. If Amendment, Date of Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)			-	X	Form filed by One Repo	orting Person n One Reporting Person			
SOUTH SAN FRANCISCO	СА	94080							
(City)	(State)	(Zip)	—						
		Table I - Non-De	rivative Securities Acquired, Disposed of, or Benefic	cially Own	ned				

Γ₅ Δ . . T. 0 24 04 . 4.0 urition A uirod (A)

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date,		tion ıstr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	 Transaction(s) (Instr. 3 and 4) 		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		5. Number Derivative Securities Acquired Disposed (Instr. 3, 4 5)	e s (A) or l of (D)	6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		derlying	8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (Right to Buy)	\$0.55	04/04/2025		Α		122,500		(1)	04/04/2035	Common Stock	122,500	\$0	122,500	D	
Restricted Stock Units (RSUs)	(2)	04/04/2025		Α		113,750		(3)	03/02/2029	Common Stock	113,750	\$0	113,750	D	

Explanation of Responses:

1. The option vests as to 2.0833% of the total award monthly, beginning on May 4, 2025, with 100% of the award being vested and exercisable on April 4, 2029, subject to the reporting person's provision of service to the issuer on each vesting date.

2. Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.

3. The RSUs vest as to 1/4th of the total award annually beginning on March 2, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.

/s/ David Pauling as attorney-in- fact for Hans-Peter Gerber	04/08/2025
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.